Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis
International Journal of Clinical and Experimental Pathology · 2025
DOI: 10.62347/bnvx1803 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Clinical and Experimental Pathology, 2025. Verfasst von Min Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory, Affiliated Hospital Chengdu University Chengdu, Sichuan, China. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory, Affiliated Hospital Chengdu University Chengdu, Sichuan, China.
- Department of Respiratory, The First People's Hospital of Neijiang Neijiang, Sichuan, China.
- Department of Oncology, Affiliated Hospital Chengdu University Chengdu, Sichuan, China.
Zitieren
APA
Xu, M., Cui, R., & Yu, X. (2025). Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis. International Journal of Clinical and Experimental Pathology. https://doi.org/10.62347/bnvx1803
Vancouver
Xu M, Cui R, Yu X. Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis. International Journal of Clinical and Experimental Pathology. 2025. doi:10.62347/bnvx1803
BibTeX
@article{Xu2025,
author = {Xu, Min and Cui, Ran and Yu, Xinlin},
title = {Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis},
journal = {International Journal of Clinical and Experimental Pathology},
year = {2025},
doi = {10.62347/bnvx1803}
}
EUVIMED